Aging is not officially classified as a disease by any major health authority, but the question is far from settled. A growing number of researchers argue that aging meets the biological criteria for a disease, while most medical institutions and evolutionary biologists maintain it is a natural process. The debate matters more than it might seem: how we classify aging shapes what gets funded, what gets approved as treatment, and what your insurance will cover.
What Biology Actually Shows
At the cellular level, aging follows a remarkably consistent pattern of breakdown. A landmark 2013 paper in the journal Cell identified nine biological hallmarks that drive aging across species: genomic instability, telomere shortening, changes in gene expression patterns, failure of protein maintenance, disrupted nutrient signaling, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered communication between cells. These aren’t vague descriptions of “getting older.” They are specific, measurable processes that accumulate over time and eventually cause the conditions we associate with old age, from heart disease to dementia to cancer.
Cellular senescence is one of the most studied of these hallmarks. When a cell becomes senescent, it permanently stops dividing and begins behaving differently, releasing signals that can damage neighboring cells and the surrounding tissue. Early in life, this process actually suppresses tumor growth by stopping damaged cells from multiplying. But as senescent cells accumulate with age, they begin promoting the very diseases they once helped prevent, including cancer. The same mechanism that protects you at 25 harms you at 75.
This is one reason proponents of the “aging is a disease” camp find the distinction between aging and disease so artificial. The underlying mechanism is the same in both cases. What differs is the rate of progression.
The Case for Calling Aging a Disease
The strongest version of this argument comes from researchers who point out that aging has identifiable causes, a predictable progression, and measurable biomarkers, all features we use to define other diseases. If you discovered a condition that caused progressive organ failure, immune decline, cognitive deterioration, and eventually death in 100% of people who had it, you would call it a disease. The fact that everyone gets it, proponents argue, doesn’t make it less of one.
Harvard geneticist David Sinclair has been the most visible champion of this view. His central claim is that aging results from a loss of biological information at the cellular level, specifically in the systems that control which genes are turned on and off. He has promoted the idea that this process can be reversed, pointing to mouse experiments using reprogramming factors (proteins originally used to turn adult cells back into stem cells) that appeared to restore youthful function in aged tissue. Critics have noted that many of his broader claims, particularly around diet timing and age-reversal supplements, rest on limited or preliminary evidence. But his core framing, that aging is a treatable biological process rather than an inevitability, has reshaped the conversation.
Practically, proponents argue that disease classification would unlock funding and drug development. History supports this. When conditions like autism were formally classified as disorders, research funding increased, diagnostic tools improved, and pharmaceutical companies invested in treatments. Right now, many aging research projects aren’t designed to maximize healthy years of life because there’s no formal disease target to aim at. Classification would give researchers a framework to run clinical trials that target aging itself rather than one disease at a time.
The Case Against
Evolutionary biology offers a fundamentally different lens. The classic theory of aging, developed by Peter Medawar and George Williams and formalized by W.D. Hamilton, explains why mortality rises with age in purely evolutionary terms. As individuals get older, less of their lifetime fertility remains, so their continued survival contributes less and less to reproductive fitness. Natural selection therefore acts more weakly to reduce mortality at older ages. Aging, in this view, isn’t a malfunction. It’s the predictable result of declining evolutionary pressure.
This doesn’t mean evolution “designed” aging. It means there was never strong selective pressure to prevent it. Some researchers have extended this framework to explain why certain species, like some tortoises and rockfish, show minimal aging: in their ecological niches, older individuals still contribute meaningfully to reproduction or to the survival of offspring, keeping selective pressure high across the lifespan.
The World Health Organization weighed in on this debate directly. During the development of ICD-11, the global system used to classify diseases, WHO initially proposed including “old age” as a diagnostic category. It also created an extension code that described aging-related processes as “pathological.” After significant pushback, both were revised. The word “pathological” was replaced with “biological,” and the WHO affirmed that aging is “globally accepted as a normal human attribute, with longevity being a privilege that we all hope to enjoy.” Instead of classifying aging itself, WHO introduced the concept of “age-related decline in intrinsic capacity,” a way to track the loss of physical and mental function without labeling the aging process as disease.
Why the Label Matters for Treatment
The most concrete consequence of this debate is what happens in clinical trials and drug approvals. Currently, the FDA does not recognize aging as a condition that drugs can be approved to treat. Every anti-aging intervention has to be tested against a specific disease: diabetes, heart failure, Alzheimer’s. This creates a bottleneck. If a drug slows aging broadly but doesn’t produce dramatic results for any single condition, it may never reach patients.
The TAME trial (Targeting Aging with Metformin) is designed to test whether this bottleneck can be broken. The study plans to enroll 3,000 people ages 65 to 79 across roughly 14 centers in the United States. Instead of measuring metformin’s effect on one disease, it will track time to a composite outcome that includes cardiovascular events, cancer, dementia, and death. If metformin delays the onset of multiple age-related conditions simultaneously, the trial’s designers argue, it would demonstrate that targeting aging biology directly is a viable medical strategy. A positive result could create a regulatory precedent for approving drugs that target aging itself.
What Changes if Aging Becomes a Disease
If aging were formally classified as a disease, the ripple effects would extend well beyond the lab. Funding bodies could use metrics like quality-adjusted life years to evaluate aging research, the same tools already used for cancer and heart disease programs. Pharmaceutical companies would have a clear incentive to develop drugs targeting aging biology, because there would be an approved indication to sell into. Insurance coverage could expand to include preventive interventions aimed at slowing biological aging rather than just treating its consequences after they appear.
The shift in language is already underway in some corners of medicine. Some institutions have begun rebranding programs around “longevity medicine,” a framework built on precision prevention, lifestyle optimization, and whole-person care. The term is deliberately forward-looking: it frames aging not as decline to be managed but as a biological process to be optimized. Whether or not aging is ever officially called a disease, this practical shift toward treating aging biology is gaining ground.
The Middle Ground Most Scientists Occupy
Most researchers working on aging don’t fall neatly into either camp. The emerging consensus is something like this: aging is not a disease in the traditional sense, because it is universal, has clear evolutionary origins, and is not caused by a single pathogen or malfunction. But the biological processes that drive aging are the same ones that cause age-related diseases, and targeting those processes directly could prevent or delay multiple conditions at once. Whether you call that “treating a disease” or “intervening in a biological process” may matter less than whether the interventions actually work.
The real question underneath the semantic debate is a practical one: should medicine wait for diseases to appear and then treat them individually, or should it target the shared biology that makes all of them more likely? The answer to that question is shifting, regardless of what we decide to call aging.